Successful Treatment of Cor Pulmonale in Drug-Resistant Tuberculosis-Related ARDS: A Case Report
Downloads
Introduction: One of the biggest challenges in global tuberculosis (TB) control is the spread of drug-resistant TB. Chronic cor pulmonale is confirmed in a pulmonary TB patient through the mechanism of pulmonary hypertension (PH). Tuberculosis is one of the causes of respiratory failure requiring mechanical ventilation. However, cases of TB requiring mechanical ventilation as the primary cause of respiratory failure are rare. Tuberculous acute respiratory distress syndrome (ARDS) is rare, but it has a very poor prognosis when it does occur.
Case: A 48-year-old female arrived with chronic cor pulmonale decompensated symptoms with drug-resistant pulmonary TB diagnosed by echocardiography. The patient developed ARDS during treatment. Initially, the patient was treated with loop diuretics, oxygen treatment, vasodilators, digitalis, anticoagulant medication, bronchodilators, and empirical antibiotics. As her condition deteriorated, the patient was put on mechanical ventilation and anti-TB medication. The patient’s health improved, and she was allowed to return home.
Conclusion: Acute respiratory distress syndrome patients associated with drug-resistant TB may experience decompensated chronic cor pulmonale. In this instance, the main diagnostic method for cor pulmonale is echocardiography. Seldom is drug-resistant pulmonary TB associated with ARDS that results in cor pulmonale being documented. Positive results are linked to early diagnosis and treatment. Following therapy, the patient’s health improved, and the patient was permitted to return home with the prescribed drugs.
Khawbung JL, Nath D, Chakraborty S. Drug Resistant Tuberculosis: A Review. Comp Immunol Microbiol Infect Dis 2021; 74: 101574. [PubMed]
Singh R, Dwivedi SP, Gaharwar US, et al. Recent Updates on Drug Resistance in Mycobacterium tuberculosis. J Appl Microbiol 2020; 128: 1547–1567. [PubMed]
Sudarsan TI, Thomas L, Samprathi A, et al. Tuberculous ARDS is associated with Worse Outcome when Compared with Non-Tuberculous Infectious ARDS. J Crit Care 2021; 61: 138–143. [PubMed]
World Health Organization (WHO). Global Tuberculosis Report 2022. Geneva, https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2022 (2022).
Mandoli GE, Sciaccaluga C, Bandera F, et al. Cor Pulmonale: The Role of Traditional and Advanced Echocardiography in the Acute and Chronic Settings. Heart Fail Rev 2021; 26: 263–275. [PubMed]
Nagwanshi J, Gathoria M, Harinkhede A, et al. Study Clinical, Radiological, Electrocardiographic, and Echocardiographic Changes in Chronic Corpulmonale. Asian J Pharm Clin Res 2023; 16: 167–170. [Journal]
Savonenkova L, Kolchin D, Ruzov V, et al. Chronic Pulmonary Heart Disease in the Structure of Fatal Outcomes in Pulmonary Tuberculosis. Tuberc Lung Dis 2023; 101: 13–19. [Journal]
Zhang Y, Li X, Li S, et al. Immunotherapy for Pulmonary Arterial Hypertension: From the Pathogenesis to Clinical Management. Int J Mol Sci; 25. Epub ahead of print August 2024. [PubMed]
Shamna H, Anusreeraj R, Shaiju S. A Case Report on Cor Pulmonale. Indian Journal of Pharmacy and Pharmacology 2022; 2022: 16962. [Journal]
Brenner SK, Azam TU, Parrillo JE, et al. Right Ventricular Dysfunction in Critically Ill Patients with COVID-19. The American Journal of Cardiology 2022; 168: 176–178. [PubMed]
Simonneau G, Montani D, Celermajer DS, et al. Haemodynamic Definitions and Updated Clinical Classification of Pulmonary Hypertension. Eur Respir J; 53. Epub ahead of print January 2019. [PubMed]
Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension: Developed by the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J 2022; 43: 3618–3731. [Journal]
Humbert M, Guignabert C, Bonnet S, et al. Pathology and Pathobiology of Pulmonary Hypertension: State of the Art and Research Perspectives. Eur Respir J; 53. Epub ahead of print January 2019. [PubMed]
Yoo HHB, Marin FL. Treating Inflammation Associated with Pulmonary Hypertension: An Overview of the Literature. Int J Gen Med 2022; 15: 1075–1083. [PubMed]
Papolos AI, Schiller NB, Belzer A, et al. Pulmonary Dead Space Monitoring: Identifying Subjects with ARDS at Risk of Developing Right Ventricular Dysfunction. Respir Care 2019; 64: 1101–1108. [PubMed]
Arrigo M, Huber LC, Winnik S, et al. Right Ventricular Failure: Pathophysiology, Diagnosis and Treatment. Card Fail Rev 2019; 5: 140–146. [PubMed]
Agrawal V, Lahm T, Hansmann G, et al. Molecular Mechanisms of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension: Focus on the Coronary Vasculature, Sex Hormones, and Glucose/Lipid Metabolism. Cardiovasc Diagn Ther 2020; 10: 1522–1540. [PubMed]
Petit M, Jullien E, Vieillard-Baron A. Right Ventricular Function in Acute Respiratory Distress Syndrome: Impact on Outcome, Respiratory Strategy and Use of Veno-Venous Extracorporeal Membrane Oxygenation. Front Physiol 2021; 12: 797252. [PubMed]
Revercomb L, Hanmandlu A, Wareing N, et al. Mechanisms of Pulmonary Hypertension in Acute Respiratory Distress Syndrome (ARDS). Front Mol Biosci 2020; 7: 624093. [PubMed]
Allwood BW, Byrne A, Meghji J, et al. Post-Tuberculosis Lung Disease: Clinical Review of an Under-Recognised Global Challenge. Respiration 2021; 100: 751–763. [PubMed]
Louw EH, Van Heerden JA, Kalla IS, et al. Scoping Review of Post-TB Pulmonary Vascular Disease: Proceedings from the 2nd International Post-Tuberculosis Symposium. Pulm Circ 2024; 14: e12424. [PubMed]
van Heerden JK, Louw EH, Thienemann F, et al. The Prevalence of Pulmonary Hypertension in Post-Tuberculosis and Active Tuberculosis Populations: A Systematic Review and Meta-Analysis. Eur Respir Rev; 33. Epub ahead of print January 2024. [PubMed]
Rajeev GS. Pulmonary Hypertension in Post Tuberculosis Pulmonary Sequelae: Attention Needed. Chest 2020; 157: A406. [Journal]
See KC. Acute Cor Pulmonale in Patients with Acute Respiratory Distress Syndrome: A Comprehensive Review. World J Crit Care Med 2021; 10: 35–42. [PubMed]
Usman AA, Cevasco M, Maybauer MO, et al. Oxygenated Right Ventricular Assist Device as Part of Veno-Venopulmonary Extracorporeal Membrane Oxygenation to Support the Right Ventricle and Pulmonary Vasculature. J Cardiothorac Surg 2023; 18: 134. [PubMed]
Inampudi C, Tedford RJ, Hemnes AR, et al. Treatment of Right Ventricular Dysfunction and Heart Failure in Pulmonary Arterial Hypertension. Cardiovasc Diagn Ther 2020; 10: 1659–1674. [PubMed]
Monteagudo-Vela M, Tindale A, Monguió-Santín E, et al. Right Ventricular Failure: Current Strategies and Future Development. Front Cardiovasc Med 2023; 10: 998382. [PubMed]
Arrigo M, Price S, Harjola VP, et al. Diagnosis and Treatment of Right Ventricular Failure Secondary to Acutely Increased Right Ventricular Afterload (Acute Cor Pulmonale): A Clinical Consensus Statement of the Association for Acute CardioVascular Care of the European Society of Cardiology. Eur hHeart Journal Acute Cardiovasc Care 2024; 13: 304–312. [PubMed]
Chopra N, Shankar SH, Biswas S, et al. Pulmonary Tuberculosis Presenting as Acute Respiratory Distress Syndrome. BMJ Case Rep; 14. Epub ahead of print January 2021. [PubMed]
Binh NG, Manabe T, Co DX, et al. Tuberculosis-Induced Acute Respiratory Distress Syndrome Treated with Veno-Venous Extracorporeal Membrane Oxygenation. Respir Med Case Reports 2019; 28: 100900. [PubMed]
Chaudhry D, Tyagi D. Tuberculosis in Intensive Care Unit. Indian J Crit Care Med 2021; 25: S150–S154. [PubMed]
Farhat M, Cox H, Ghanem M, et al. Drug-Resistant Tuberculosis: A Persistent Global Health Concern. Nat Rev Microbiol 2024; 22: 617–635. [Journal]
Liebenberg D, Gordhan BG, Kana BD. Drug Resistant Tuberculosis: Implications for Transmission, Diagnosis, and Disease Management. Front Cell Infect Microbiol 2022; 12: 943545. [PubMed]
World Health Organization (WHO). WHO Consolidated Guidelines on Tuberculosis: Module 3: Diagnosis: Rapid Diagnostics for Tuberculosis Detection, 2021 Update. Geneva, https://www.who.int/publications/i/item/9789240029415 (2021).
World Health Organization (WHO). WHO Consolidated Guidelines on Tuberculosis, Module 4: Treatment - Drug-Resistant Tuberculosis Treatment. Geneva, https://www.who.int/publications/i/item/9789240007048 (2020).
Copyright (c) 2025 Amalia Sutoyo

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.